Ertapenem for diabetic foot infections

Drugs of Today

Volumn 42, Issue 11, 2006, Pages 695-701

  Rogers, Lee C ^a   Bevilacqua, Nicholas J ^a   Armstrong, David G ^a,b  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZTREONAM; CARBAPENEM; CEFALEXIN; CEFTRIAXONE; CLINDAMYCIN; ERTAPENEM; IMIPENEM; LINEZOLID; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIGECYCLINE; TROVAFLOXACIN;

ANKLE BRACHIAL INDEX; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BIOEQUIVALENCE; CLINICAL FEATURE; CLINICAL TRIAL; DEBRIDEMENT; DIABETIC FOOT; DIARRHEA; DRUG COST; DRUG MECHANISM; DRUG MUSCLE LEVEL; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEALTH CARE COST; HUMAN; LASER DOPPLER FLOWMETRY; LENGTH OF STAY; LUNG CANCER; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NAUSEA; PLASMA HALF LIFE; REVIEW; SKIN INFECTION; TRANSCUTANEOUS OXYGEN MONITORING; TREATMENT RESPONSE; VASCULAR DISEASE; WOUND HEALING;

ANTI-BACTERIAL AGENTS; BETA-LACTAMS; DIABETIC FOOT; HUMANS;

EID: 33846132260     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2006.42.11.1037370     Document Type: Review

References (57)

1. Singh, N., Armstrong, D.G., Lipsky, B.A. Preventing foot ulcers in patients with diabetes. JAMA 2005, 293: 217-28.
2. Lipsky, B.A., Berendt, A.R., Embil, J., De Lalla, F. Diagnosing and treating diabetic foot infections. Diabetes Metab Res Rev 2004, 20 (Suppl. 1): S56-64.
3. Reiber, G.E., Boyko, E.J., Smith, D.G. Lower extremity foot ulcers and amputations in diabetes. In: Harris, M.I., Cowie, C., Stern, M.P. (Eds.). Diabetes in America, 2nd ed. United Government Printing Office (NIH Publ. 95-1468), Washington, D.C., 1995.
4. Pecoraro, R.E., Reiber, G.E., Burgess, E.M. Pathways to diabetic limb amputation: Basis for prevention. Diabetes Care 1990, 13: 513-21.
5. Centers for Disease Control and Prevention. Surveillance Summary; Non-traumatic Amputations. http://www.cdc.gov/diabetes/statistics/survl99/chap1/ amputation.htm. Accessed September 6, 2006.
6. Goldner, M.G. The fate of the second leg in the diabetic amputee. Diabetes 1960, 9: 100-3.
7. Jeffcoate, W.J., Chipchase, S.Y., Ince, P., Game, F.L. Assessing the outcome of the management of diabetic foot ulcers using ulcer-related and person-related measures. Diabetes Care 2006, 29: 1784-7.
8. Ramsey, S.D., Newton, K., Blough, D. et al. Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care 1999, 22: 382-7.
9. Armstrong, D.G., Lavery, L.A., Harkless, L.B. Validation of a diabetic wound classification system. The contribution of depth, infection, and ischemia to risk of amputation. Diabetes Care 1998, 21: 855-9.
10. Frykberg, R.G., Lavery, L.A., Pham, H., Harvey, C., Harkless, L., Veves, A. Role of neuropathy and high foot pressures in diabetic foot ulceration. Diabetes Care 1998, 21: 1714-9.
11. Lavery, L.A., Vela, S.A., Lavery, D.C., Quebedeaux, T. L. Reducing dynamic foot pressures in high-risk diabetic subjects with foot ulcerations. A comparison of treatments. Diabetes Care 1996, 19: 818-21.
12. Armstrong, D.G., Short, B., Nixon, B.P., Boulton, A.J.M. Technique for fabrication of an "instant" total contact cast for treatment of neuropathic diabetic foot ulcers. J Amer Pediatr Med Assn 2002, 92: 405-8.
13. Lipsky, B.A., Berendt, A.R., Deery, H.G. et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2004, 39: 885-910.
14. O'Meara, S., Nelson, E.A., Golder, S., Dalton, J.E., Craig, D., Iglesias, C. Systematic review of methods to diagnose infection in foot ulcers in diabetes. Diabet Med 2006, 23: 341-7.
15. Armstrong, D.G., Lavery, L.A., Sariaya, M., Ashry, H. Leukocytosis is a poor indicator of acute osteomyelitis of the foot in diabetes mellitus. J Foot Ankle Surg 1996, 35: 280-3.
16. Frykberg, R.G. Charcot arthropathy: Pathogenesis and management. Wounds 2000, 12 (6 Suppl. B): 35B-42.
17. El-Maghraby, T.A., Moustafa, H.M., Pauwels, E.K. Nuclear medicine methods for evaluation of skeletal infection among other diagnostic modalities. Q J Nucl Med Mol Imaging 2006, 50: 167-92.
18. Grayson, M.L., Balaugh, K., Levin, E., Karchmer, A.W. Probing to bone in infected pedal ulcers. A clinical sign of underlying osteomyelitis in diabetic patients. J Am Med Assoc 1995, 273: 721-3.
19. Karchmer, A.W. Microbiology and treatment of diabetic foot infections. In: Veves, A., Giurini, J.M., LoGerfo, F.W. (Eds.). The Diabetic Foot, Second ed. Humana Press Totowa, 2006, 255-68.
20. Apelqvist, J., Castenfors, J., Larsson, J., Stenstrom, A., Agardh, C.D. Wound classification is more important than site of ulceration in the outcome of diabetic foot ulcers. Diabet Med 1989, 6: 526-30.
21. Rauwerda, J.A. Foot debridement: Anatomic knowledge is mandatory. Diabetes Metab Res Rev 2000, 16 (Suppl. 1): S23-26.
22. Attinger, C.E., Bulan, E., Blume, P.A. Surgical debridement: The key to successful wound healing and reconstruction. Clin Pediatr Med Surg 2000, 17: 599-630.
23. Steed, D.L., Donohoe, D., Webster, M.W., Lindsley, L. Effect of extensive debridement and treatment on the healing of diabetic foot ulcers. Diabetic Ulcer Study Group J Am Coll Surg 1996, 183: 61-4.
24. Lipsky, B.A., Armstrong, D.G., Citron, D.M., Tice, A.D., Morgenstern, D.E., Abramson, M.A. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): Prospective, randomised, controlled, double-blinded, multicentre trial. Lancet 2005, 366: 1695-703.
25. Lipsky, B.A. A current approach to diabetic foot infections. Curr Infect Dis Rep 1999, 1: 253-60.
26. LaPlante, K.L., Rybak, M.J. Daptomycin - A novel antibiotic against Gram-positive pathogens. Expert Opin Pharmacother Nov 2004, 5: 2321-31.
27. Dang, C.N., Prasad, Y.D., Boulton, A.J., Jude, E.B. Methicillin- resistant Staphylococcus aureus in the diabetic foot clinic: A worsening problem. Diabet Med 2003, 20: 159-61.
28. Roghmann, M.C., Siddiqui, A., Plaisance, K., Standiford, H. MRSA colonization and the risk of MRSA bacteraemia in hospitalized patients with chronic ulcers. J Hosp Infect 2001, 47: 98-103.
29. Troillet, N., Carmeli, Y., Samore, M.H. et al. Carriage of methicillin-resistant Staphylococcus aureus at hospital admission. Infect Control Hosp Epidemiol 1998, 19: 181-5.
30. Vidhani, S., Mathur, M.D., Mehndiratta, P.L., Rizvi, M. Methicillin-resistant Staphylococcus aureus (MRSA): The associated risk factors. Indian J Pathol Microbiol 2003, 46: 676-9.
31. Huang, S.S., Platt, R. Risk of methicillin-resistant Staphylococcus aureus infection after previous infection or colonization. Clin Infect Dis 2003, 36: 281-5.
32. Warshawsky, B., Hussain, Z., Gregson, D.B. et al. Hospital- and community-based surveillance of methicillin-resistant Staphylococcus aureus: Previous hospitalization is the major risk factor. Infect Control Hosp Epidemiol 2000, 21: 724-7.
33. Jernigan, J.A., Pullen, A.L., Flowers, L., Bell, M., Jarvis, W.R. Prevalence of and risk factors for colonization with methicillin-resistant Staphylococcus aureus at the time of hospital admission. Infect Control Hosp Epidemiol 2003, 24: 409-14.
34. Furuno, J.P., Harris, A.D., Wright, M.O. et al. Prediction rules to identify patients with methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci upon hospital admission. Am J Infect Control 2004, 32: 436-40.
35. DiNubile, M.J., Lipsky, B.A. Complicated infections of skin and skin structures: When the infection is more than skin deep. J Antimicrob Chemother 2004, 53 (Suppl. 2): ii37-50.
36. Shah, P.M., Isaacs, R.D. Ertapenem, the first of a new group of carbapenems. J Antimicrob Chemother 2003, 52: 538-42.
37. Nix, D.E., Majumdar, A.K., DNubile, M.J. Pharmacokinetics and pharmacodynamics of ertapenem: An overview for clinicians. J Antimicrob Chemother 2004, 53 (Suppl. 2): ii23-28.
38. Keating, G.M., Perry, C.M. Ertapenem: A review of its use in the treatment of bacterial infections. Drugs 2005, 65: 2151-78.
39. Hammond, M.L. Ertapenem: A Group 1 carbapenem with distinct antibacterial and pharmacological properties. J Antimicrob Chemother 2004, 53 (Suppl. 2): ii7-9.
40. Goldstein, E.J., Citron, D.M., Merriam, C.V., Warren, Y., Tyrrell, K.L., Gesser, R.M. General microbiology and in vitro susceptibility of anaerobes isolated from complicated skin and skin-structure infections in patients enrolled in a comparative trial of ertapenem versus piperacillin-tazobactam. Clin Infect Dis 2002, 35 (Suppl. 1): S119-25.
41. Aldridge, K.E. Ertapenem (MK-0826), a new carbapenem: Comparative in vitro activity against clinically significant anaerobes. Diagn Microbiol Infect Dis 2002, 44: 181-6.
42. Burkhardt, O., Brunner, M., Schmidt, S., Grant, M., Tang, Y., Derendorf, H. Penetration of ertapenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers measured by in vivo microdialysis. J Antimicrob Chemother 2006, 58: 632-6.
43. Chen, M., Nafziger, A.N., Drusano, G.L., Ma, L., Bertino, J.S. Jr. Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults. Antimicrob Agents Chemother 2006, 50: 1222-7.
44. Gesser, R.M., McCarroll, K.A., Woods, G.L. Efficacy of ertapenem against methicillin-susceptible Staphylococcus aureus in complicated skin/skin structure infections: Results of a double-blind clinical trial versus piperacillin-tazobactam. Int J Antimicrob Agents 2004, 23: 235-9.
45. Graham, D.R., Lucasti, C., Malafaia, O. et al. Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: Results of a prospective, randomized, double-blind multicenter study. Clin Infect Dis 2002, 34: 1460-8.
46. Department of Health and Human Services. Food and Drug Administration NDA 21-337/S-019. October 14, 2005.
47. Clinical trial design in diabetic foot infections. Presentation to the Food and Drug Administration. Washington, D.C., October 28, 2003.
48. Tice, A.D. Ertapenem: A new opportunity for outpatient parenteral antimicrobial therapy. J Antimicrob Chemother 2004, 53 (Suppl. 2): ii83-86.
49. Zhanel, G.G., Johanson, C., Embil, J.M. et al. Ertapenem: Review of a new carbapenem. Expert Rev Anti Infect Ther 2005, 3: 23-39.
50. Gesser, R.M., McCarroll, K.A., Woods, G.L. Evaluation of outpatient treatment with ertapenem in a double-blind, controlled clinical trial of complicated skin/skin structure infections. J Infect 2004, 48: 32-8.
51. Wilson, S.E., Turpin, R.S., Hu, X.H., Sullivan, E., Mansley, E.C., Ma, L. Does initial choice of antimicrobial therapy affect length of stay for patients with complicated intra-abdominal infections? Am Surg 2005, 71: 816-20.
52. Teppler, H., Gesser, R.M., Friedland, I.R. et al. Safefy and tolerability of ertapenem. J Antimicrob Chemother 2004, 53 (Suppl. 2): ii75-81.
53. Elliott, E., Brink, A.J., van Greune, J. et al. In vivo development of ertapenem resistance in a patient with pneumonia caused by Klebsiella pneumoniae with an extended-spectrum beta-lactamase. Clin Infect Dis 2006, 42: e95-8.
54. Quale, J., Bratu, S., Gupta, J., Landman, D. Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 2006, 50: 1633-41.
55. Livermore, D.M., Mushtaq, S., Warner, M. Selectivity of ertapenem for Pseudomonas aeruginosa mutants cross-resistant to other carbapenems. J Antimicrob Chemother 2005, 55: 306-11.
56. Livermore, D.M., Sefton, A.M., Scott, G.M. Properties and potential of ertapenem. J Antimicrob Chemother 2003, 52: 331-44.
57. Jacqueline, C., Caillon, J., Grossi, O. et al. In vitro and in vivo assessment of linezolid combined with ertapenem: A highly synergistic combination against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2006, 50: 2547-9.